nodes	percent_of_prediction	percent_of_DWPC	metapath
Aprepitant—breast cancer—Medroxyprogesterone Acetate—uterine cancer	0.602	1	CpDpCtD
Aprepitant—CYP3A7-CYP3A51P—Progesterone—uterine cancer	0.0416	0.149	CbGbCtD
Aprepitant—CYP3A7—Progesterone—uterine cancer	0.0416	0.149	CbGbCtD
Aprepitant—CYP2C9—Medroxyprogesterone Acetate—uterine cancer	0.0316	0.113	CbGbCtD
Aprepitant—CYP3A5—Progesterone—uterine cancer	0.0312	0.112	CbGbCtD
Aprepitant—CYP2C19—Progesterone—uterine cancer	0.0252	0.0901	CbGbCtD
Aprepitant—CYP1A2—Progesterone—uterine cancer	0.0232	0.0831	CbGbCtD
Aprepitant—CYP2C9—Progesterone—uterine cancer	0.0209	0.0749	CbGbCtD
Aprepitant—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0184	0.0657	CbGbCtD
Aprepitant—CYP3A5—Etoposide—uterine cancer	0.014	0.05	CbGbCtD
Aprepitant—CYP3A4—Progesterone—uterine cancer	0.0122	0.0436	CbGbCtD
Aprepitant—CYP1A2—Etoposide—uterine cancer	0.0104	0.0372	CbGbCtD
Aprepitant—CYP3A4—Etoposide—uterine cancer	0.00545	0.0195	CbGbCtD
Aprepitant—CYP3A4—Doxorubicin—uterine cancer	0.00372	0.0133	CbGbCtD
Aprepitant—TACR3—smooth muscle tissue—uterine cancer	0.00125	0.259	CbGeAlD
Aprepitant—TACR3—female reproductive system—uterine cancer	0.000961	0.2	CbGeAlD
Aprepitant—TACR1—smooth muscle tissue—uterine cancer	0.000483	0.1	CbGeAlD
Aprepitant—TACR1—renal system—uterine cancer	0.000465	0.0966	CbGeAlD
Aprepitant—TACR1—female reproductive system—uterine cancer	0.000372	0.0774	CbGeAlD
Aprepitant—TACR1—lymph node—uterine cancer	0.000218	0.0453	CbGeAlD
Aprepitant—CYP3A5—uterine cervix—uterine cancer	0.000149	0.0311	CbGeAlD
Aprepitant—CYP1A2—renal system—uterine cancer	0.000145	0.0301	CbGeAlD
Aprepitant—CYP3A5—renal system—uterine cancer	0.00014	0.0291	CbGeAlD
Aprepitant—CYP2C19—vagina—uterine cancer	0.000129	0.0267	CbGeAlD
Aprepitant—CYP2C9—female reproductive system—uterine cancer	0.00011	0.0229	CbGeAlD
Aprepitant—CYP3A4—renal system—uterine cancer	0.000105	0.0218	CbGeAlD
Aprepitant—CYP3A5—female gonad—uterine cancer	0.000102	0.0212	CbGeAlD
Aprepitant—CYP3A5—vagina—uterine cancer	0.000101	0.0211	CbGeAlD
Aprepitant—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	9.26e-05	0.000843	CcSEcCtD
Aprepitant—Discomfort—Etoposide—uterine cancer	9.21e-05	0.000839	CcSEcCtD
Aprepitant—Breast disorder—Epirubicin—uterine cancer	9.21e-05	0.000839	CcSEcCtD
Aprepitant—Aspartate aminotransferase increased—Epirubicin—uterine cancer	9.18e-05	0.000836	CcSEcCtD
Aprepitant—Toxic epidermal necrolysis—Epirubicin—uterine cancer	9.18e-05	0.000836	CcSEcCtD
Aprepitant—Hypersensitivity—Dactinomycin—uterine cancer	9.1e-05	0.000829	CcSEcCtD
Aprepitant—Gastritis—Epirubicin—uterine cancer	9.02e-05	0.000822	CcSEcCtD
Aprepitant—Confusional state—Etoposide—uterine cancer	9.01e-05	0.000821	CcSEcCtD
Aprepitant—Muscular weakness—Epirubicin—uterine cancer	8.99e-05	0.000819	CcSEcCtD
Aprepitant—Alanine aminotransferase increased—Epirubicin—uterine cancer	8.99e-05	0.000819	CcSEcCtD
Aprepitant—Anaphylactic shock—Etoposide—uterine cancer	8.94e-05	0.000814	CcSEcCtD
Aprepitant—Infection—Etoposide—uterine cancer	8.88e-05	0.000809	CcSEcCtD
Aprepitant—Abdominal distension—Epirubicin—uterine cancer	8.87e-05	0.000808	CcSEcCtD
Aprepitant—Asthenia—Dactinomycin—uterine cancer	8.86e-05	0.000807	CcSEcCtD
Aprepitant—Blood creatinine increased—Doxorubicin—uterine cancer	8.84e-05	0.000805	CcSEcCtD
Aprepitant—Dysphagia—Epirubicin—uterine cancer	8.81e-05	0.000802	CcSEcCtD
Aprepitant—Dehydration—Doxorubicin—uterine cancer	8.77e-05	0.000799	CcSEcCtD
Aprepitant—Thrombocytopenia—Etoposide—uterine cancer	8.75e-05	0.000797	CcSEcCtD
Aprepitant—Tachycardia—Etoposide—uterine cancer	8.73e-05	0.000794	CcSEcCtD
Aprepitant—Skin disorder—Etoposide—uterine cancer	8.68e-05	0.000791	CcSEcCtD
Aprepitant—Hyperhidrosis—Etoposide—uterine cancer	8.64e-05	0.000787	CcSEcCtD
Aprepitant—Abdominal pain upper—Doxorubicin—uterine cancer	8.62e-05	0.000784	CcSEcCtD
Aprepitant—Hypokalaemia—Doxorubicin—uterine cancer	8.59e-05	0.000782	CcSEcCtD
Aprepitant—Breast disorder—Doxorubicin—uterine cancer	8.53e-05	0.000776	CcSEcCtD
Aprepitant—Anorexia—Etoposide—uterine cancer	8.52e-05	0.000776	CcSEcCtD
Aprepitant—Toxic epidermal necrolysis—Doxorubicin—uterine cancer	8.5e-05	0.000773	CcSEcCtD
Aprepitant—Aspartate aminotransferase increased—Doxorubicin—uterine cancer	8.5e-05	0.000773	CcSEcCtD
Aprepitant—Diarrhoea—Dactinomycin—uterine cancer	8.45e-05	0.000769	CcSEcCtD
Aprepitant—CYP3A4—female reproductive system—uterine cancer	8.4e-05	0.0175	CbGeAlD
Aprepitant—Hypotension—Etoposide—uterine cancer	8.35e-05	0.000761	CcSEcCtD
Aprepitant—Gastritis—Doxorubicin—uterine cancer	8.35e-05	0.00076	CcSEcCtD
Aprepitant—Alanine aminotransferase increased—Doxorubicin—uterine cancer	8.32e-05	0.000758	CcSEcCtD
Aprepitant—Muscular weakness—Doxorubicin—uterine cancer	8.32e-05	0.000758	CcSEcCtD
Aprepitant—Dysuria—Epirubicin—uterine cancer	8.24e-05	0.00075	CcSEcCtD
Aprepitant—Neutropenia—Epirubicin—uterine cancer	8.24e-05	0.00075	CcSEcCtD
Aprepitant—Abdominal distension—Doxorubicin—uterine cancer	8.21e-05	0.000747	CcSEcCtD
Aprepitant—Upper respiratory tract infection—Epirubicin—uterine cancer	8.19e-05	0.000746	CcSEcCtD
Aprepitant—Dysphagia—Doxorubicin—uterine cancer	8.15e-05	0.000742	CcSEcCtD
Aprepitant—Pollakiuria—Epirubicin—uterine cancer	8.14e-05	0.000741	CcSEcCtD
Aprepitant—Photosensitivity reaction—Epirubicin—uterine cancer	8.04e-05	0.000732	CcSEcCtD
Aprepitant—Paraesthesia—Etoposide—uterine cancer	8.03e-05	0.000731	CcSEcCtD
Aprepitant—Weight increased—Epirubicin—uterine cancer	8.02e-05	0.00073	CcSEcCtD
Aprepitant—Weight decreased—Epirubicin—uterine cancer	7.97e-05	0.000726	CcSEcCtD
Aprepitant—Dyspnoea—Etoposide—uterine cancer	7.97e-05	0.000726	CcSEcCtD
Aprepitant—Hyperglycaemia—Epirubicin—uterine cancer	7.95e-05	0.000724	CcSEcCtD
Aprepitant—Somnolence—Etoposide—uterine cancer	7.95e-05	0.000724	CcSEcCtD
Aprepitant—Pneumonia—Epirubicin—uterine cancer	7.9e-05	0.00072	CcSEcCtD
Aprepitant—Infestation NOS—Epirubicin—uterine cancer	7.86e-05	0.000715	CcSEcCtD
Aprepitant—Infestation—Epirubicin—uterine cancer	7.86e-05	0.000715	CcSEcCtD
Aprepitant—Vomiting—Dactinomycin—uterine cancer	7.85e-05	0.000715	CcSEcCtD
Aprepitant—Stevens-Johnson syndrome—Epirubicin—uterine cancer	7.79e-05	0.000709	CcSEcCtD
Aprepitant—Rash—Dactinomycin—uterine cancer	7.79e-05	0.000709	CcSEcCtD
Aprepitant—Decreased appetite—Etoposide—uterine cancer	7.77e-05	0.000708	CcSEcCtD
Aprepitant—Renal failure—Epirubicin—uterine cancer	7.72e-05	0.000703	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Etoposide—uterine cancer	7.72e-05	0.000703	CcSEcCtD
Aprepitant—Fatigue—Etoposide—uterine cancer	7.71e-05	0.000702	CcSEcCtD
Aprepitant—Neuropathy peripheral—Epirubicin—uterine cancer	7.7e-05	0.000701	CcSEcCtD
Aprepitant—Stomatitis—Epirubicin—uterine cancer	7.66e-05	0.000697	CcSEcCtD
Aprepitant—Pain—Etoposide—uterine cancer	7.65e-05	0.000696	CcSEcCtD
Aprepitant—Constipation—Etoposide—uterine cancer	7.65e-05	0.000696	CcSEcCtD
Aprepitant—Conjunctivitis—Epirubicin—uterine cancer	7.64e-05	0.000695	CcSEcCtD
Aprepitant—Urinary tract infection—Epirubicin—uterine cancer	7.64e-05	0.000695	CcSEcCtD
Aprepitant—Neutropenia—Doxorubicin—uterine cancer	7.62e-05	0.000694	CcSEcCtD
Aprepitant—Dysuria—Doxorubicin—uterine cancer	7.62e-05	0.000694	CcSEcCtD
Aprepitant—Upper respiratory tract infection—Doxorubicin—uterine cancer	7.58e-05	0.00069	CcSEcCtD
Aprepitant—Pollakiuria—Doxorubicin—uterine cancer	7.53e-05	0.000686	CcSEcCtD
Aprepitant—Haematuria—Epirubicin—uterine cancer	7.49e-05	0.000682	CcSEcCtD
Aprepitant—Photosensitivity reaction—Doxorubicin—uterine cancer	7.44e-05	0.000678	CcSEcCtD
Aprepitant—Weight increased—Doxorubicin—uterine cancer	7.42e-05	0.000676	CcSEcCtD
Aprepitant—Weight decreased—Doxorubicin—uterine cancer	7.38e-05	0.000672	CcSEcCtD
Aprepitant—Feeling abnormal—Etoposide—uterine cancer	7.37e-05	0.000671	CcSEcCtD
Aprepitant—Hyperglycaemia—Doxorubicin—uterine cancer	7.36e-05	0.00067	CcSEcCtD
Aprepitant—Nausea—Dactinomycin—uterine cancer	7.34e-05	0.000668	CcSEcCtD
Aprepitant—Pneumonia—Doxorubicin—uterine cancer	7.31e-05	0.000666	CcSEcCtD
Aprepitant—Gastrointestinal pain—Etoposide—uterine cancer	7.31e-05	0.000666	CcSEcCtD
Aprepitant—Infestation NOS—Doxorubicin—uterine cancer	7.27e-05	0.000662	CcSEcCtD
Aprepitant—Infestation—Doxorubicin—uterine cancer	7.27e-05	0.000662	CcSEcCtD
Aprepitant—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	7.21e-05	0.000656	CcSEcCtD
Aprepitant—Bradycardia—Epirubicin—uterine cancer	7.18e-05	0.000654	CcSEcCtD
Aprepitant—Renal failure—Doxorubicin—uterine cancer	7.15e-05	0.000651	CcSEcCtD
Aprepitant—Neuropathy peripheral—Doxorubicin—uterine cancer	7.13e-05	0.000649	CcSEcCtD
Aprepitant—Urticaria—Etoposide—uterine cancer	7.1e-05	0.000647	CcSEcCtD
Aprepitant—Stomatitis—Doxorubicin—uterine cancer	7.09e-05	0.000645	CcSEcCtD
Aprepitant—Abdominal pain—Etoposide—uterine cancer	7.07e-05	0.000643	CcSEcCtD
Aprepitant—Body temperature increased—Etoposide—uterine cancer	7.07e-05	0.000643	CcSEcCtD
Aprepitant—Conjunctivitis—Doxorubicin—uterine cancer	7.07e-05	0.000643	CcSEcCtD
Aprepitant—Urinary tract infection—Doxorubicin—uterine cancer	7.07e-05	0.000643	CcSEcCtD
Aprepitant—Hypoaesthesia—Epirubicin—uterine cancer	7.02e-05	0.000639	CcSEcCtD
Aprepitant—Pharyngitis—Epirubicin—uterine cancer	7e-05	0.000637	CcSEcCtD
Aprepitant—Urinary tract disorder—Epirubicin—uterine cancer	6.97e-05	0.000634	CcSEcCtD
Aprepitant—Haematuria—Doxorubicin—uterine cancer	6.93e-05	0.000631	CcSEcCtD
Aprepitant—Connective tissue disorder—Epirubicin—uterine cancer	6.93e-05	0.000631	CcSEcCtD
Aprepitant—Urethral disorder—Epirubicin—uterine cancer	6.91e-05	0.00063	CcSEcCtD
Aprepitant—Erythema multiforme—Epirubicin—uterine cancer	6.67e-05	0.000607	CcSEcCtD
Aprepitant—Bradycardia—Doxorubicin—uterine cancer	6.64e-05	0.000605	CcSEcCtD
Aprepitant—Eye disorder—Epirubicin—uterine cancer	6.59e-05	0.0006	CcSEcCtD
Aprepitant—Hypersensitivity—Etoposide—uterine cancer	6.59e-05	0.0006	CcSEcCtD
Aprepitant—Tinnitus—Epirubicin—uterine cancer	6.58e-05	0.000599	CcSEcCtD
Aprepitant—Flushing—Epirubicin—uterine cancer	6.55e-05	0.000596	CcSEcCtD
Aprepitant—Cardiac disorder—Epirubicin—uterine cancer	6.55e-05	0.000596	CcSEcCtD
Aprepitant—Hypoaesthesia—Doxorubicin—uterine cancer	6.49e-05	0.000591	CcSEcCtD
Aprepitant—Pharyngitis—Doxorubicin—uterine cancer	6.48e-05	0.00059	CcSEcCtD
Aprepitant—Urinary tract disorder—Doxorubicin—uterine cancer	6.45e-05	0.000587	CcSEcCtD
Aprepitant—Asthenia—Etoposide—uterine cancer	6.41e-05	0.000584	CcSEcCtD
Aprepitant—Connective tissue disorder—Doxorubicin—uterine cancer	6.41e-05	0.000584	CcSEcCtD
Aprepitant—Angiopathy—Epirubicin—uterine cancer	6.4e-05	0.000583	CcSEcCtD
Aprepitant—Urethral disorder—Doxorubicin—uterine cancer	6.4e-05	0.000582	CcSEcCtD
Aprepitant—Immune system disorder—Epirubicin—uterine cancer	6.37e-05	0.00058	CcSEcCtD
Aprepitant—Mediastinal disorder—Epirubicin—uterine cancer	6.36e-05	0.000579	CcSEcCtD
Aprepitant—Chills—Epirubicin—uterine cancer	6.33e-05	0.000576	CcSEcCtD
Aprepitant—Pruritus—Etoposide—uterine cancer	6.33e-05	0.000576	CcSEcCtD
Aprepitant—Alopecia—Epirubicin—uterine cancer	6.23e-05	0.000567	CcSEcCtD
Aprepitant—Mental disorder—Epirubicin—uterine cancer	6.18e-05	0.000563	CcSEcCtD
Aprepitant—Erythema multiforme—Doxorubicin—uterine cancer	6.17e-05	0.000562	CcSEcCtD
Aprepitant—Erythema—Epirubicin—uterine cancer	6.14e-05	0.000559	CcSEcCtD
Aprepitant—Malnutrition—Epirubicin—uterine cancer	6.14e-05	0.000559	CcSEcCtD
Aprepitant—Diarrhoea—Etoposide—uterine cancer	6.12e-05	0.000557	CcSEcCtD
Aprepitant—Eye disorder—Doxorubicin—uterine cancer	6.1e-05	0.000555	CcSEcCtD
Aprepitant—Tinnitus—Doxorubicin—uterine cancer	6.09e-05	0.000554	CcSEcCtD
Aprepitant—Flushing—Doxorubicin—uterine cancer	6.06e-05	0.000551	CcSEcCtD
Aprepitant—Cardiac disorder—Doxorubicin—uterine cancer	6.06e-05	0.000551	CcSEcCtD
Aprepitant—Flatulence—Epirubicin—uterine cancer	6.05e-05	0.000551	CcSEcCtD
Aprepitant—Dysgeusia—Epirubicin—uterine cancer	6.01e-05	0.000547	CcSEcCtD
Aprepitant—Back pain—Epirubicin—uterine cancer	5.94e-05	0.000541	CcSEcCtD
Aprepitant—Angiopathy—Doxorubicin—uterine cancer	5.92e-05	0.000539	CcSEcCtD
Aprepitant—Dizziness—Etoposide—uterine cancer	5.91e-05	0.000538	CcSEcCtD
Aprepitant—Muscle spasms—Epirubicin—uterine cancer	5.9e-05	0.000537	CcSEcCtD
Aprepitant—Immune system disorder—Doxorubicin—uterine cancer	5.9e-05	0.000537	CcSEcCtD
Aprepitant—Mediastinal disorder—Doxorubicin—uterine cancer	5.88e-05	0.000536	CcSEcCtD
Aprepitant—Chills—Doxorubicin—uterine cancer	5.86e-05	0.000533	CcSEcCtD
Aprepitant—Alopecia—Doxorubicin—uterine cancer	5.77e-05	0.000525	CcSEcCtD
Aprepitant—Mental disorder—Doxorubicin—uterine cancer	5.72e-05	0.000521	CcSEcCtD
Aprepitant—Ill-defined disorder—Epirubicin—uterine cancer	5.7e-05	0.000519	CcSEcCtD
Aprepitant—Vomiting—Etoposide—uterine cancer	5.68e-05	0.000518	CcSEcCtD
Aprepitant—Erythema—Doxorubicin—uterine cancer	5.68e-05	0.000517	CcSEcCtD
Aprepitant—Malnutrition—Doxorubicin—uterine cancer	5.68e-05	0.000517	CcSEcCtD
Aprepitant—Anaemia—Epirubicin—uterine cancer	5.68e-05	0.000517	CcSEcCtD
Aprepitant—Rash—Etoposide—uterine cancer	5.64e-05	0.000513	CcSEcCtD
Aprepitant—Dermatitis—Etoposide—uterine cancer	5.63e-05	0.000513	CcSEcCtD
Aprepitant—Headache—Etoposide—uterine cancer	5.6e-05	0.00051	CcSEcCtD
Aprepitant—Flatulence—Doxorubicin—uterine cancer	5.6e-05	0.00051	CcSEcCtD
Aprepitant—Dysgeusia—Doxorubicin—uterine cancer	5.56e-05	0.000507	CcSEcCtD
Aprepitant—Malaise—Epirubicin—uterine cancer	5.54e-05	0.000504	CcSEcCtD
Aprepitant—Syncope—Epirubicin—uterine cancer	5.51e-05	0.000501	CcSEcCtD
Aprepitant—Back pain—Doxorubicin—uterine cancer	5.5e-05	0.0005	CcSEcCtD
Aprepitant—Muscle spasms—Doxorubicin—uterine cancer	5.46e-05	0.000497	CcSEcCtD
Aprepitant—Palpitations—Epirubicin—uterine cancer	5.43e-05	0.000494	CcSEcCtD
Aprepitant—Loss of consciousness—Epirubicin—uterine cancer	5.4e-05	0.000491	CcSEcCtD
Aprepitant—Cough—Epirubicin—uterine cancer	5.36e-05	0.000488	CcSEcCtD
Aprepitant—Convulsion—Epirubicin—uterine cancer	5.32e-05	0.000484	CcSEcCtD
Aprepitant—Nausea—Etoposide—uterine cancer	5.31e-05	0.000483	CcSEcCtD
Aprepitant—Hypertension—Epirubicin—uterine cancer	5.3e-05	0.000483	CcSEcCtD
Aprepitant—Ill-defined disorder—Doxorubicin—uterine cancer	5.27e-05	0.00048	CcSEcCtD
Aprepitant—Anaemia—Doxorubicin—uterine cancer	5.25e-05	0.000478	CcSEcCtD
Aprepitant—Chest pain—Epirubicin—uterine cancer	5.23e-05	0.000476	CcSEcCtD
Aprepitant—Myalgia—Epirubicin—uterine cancer	5.23e-05	0.000476	CcSEcCtD
Aprepitant—Arthralgia—Epirubicin—uterine cancer	5.23e-05	0.000476	CcSEcCtD
Aprepitant—Anxiety—Epirubicin—uterine cancer	5.21e-05	0.000474	CcSEcCtD
Aprepitant—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	5.19e-05	0.000473	CcSEcCtD
Aprepitant—Discomfort—Epirubicin—uterine cancer	5.17e-05	0.00047	CcSEcCtD
Aprepitant—Malaise—Doxorubicin—uterine cancer	5.12e-05	0.000466	CcSEcCtD
Aprepitant—Dry mouth—Epirubicin—uterine cancer	5.11e-05	0.000465	CcSEcCtD
Aprepitant—Syncope—Doxorubicin—uterine cancer	5.1e-05	0.000464	CcSEcCtD
Aprepitant—Confusional state—Epirubicin—uterine cancer	5.05e-05	0.00046	CcSEcCtD
Aprepitant—Palpitations—Doxorubicin—uterine cancer	5.02e-05	0.000457	CcSEcCtD
Aprepitant—Anaphylactic shock—Epirubicin—uterine cancer	5.01e-05	0.000456	CcSEcCtD
Aprepitant—Oedema—Epirubicin—uterine cancer	5.01e-05	0.000456	CcSEcCtD
Aprepitant—Loss of consciousness—Doxorubicin—uterine cancer	4.99e-05	0.000455	CcSEcCtD
Aprepitant—Infection—Epirubicin—uterine cancer	4.98e-05	0.000453	CcSEcCtD
Aprepitant—Cough—Doxorubicin—uterine cancer	4.96e-05	0.000451	CcSEcCtD
Aprepitant—Shock—Epirubicin—uterine cancer	4.93e-05	0.000449	CcSEcCtD
Aprepitant—Convulsion—Doxorubicin—uterine cancer	4.92e-05	0.000448	CcSEcCtD
Aprepitant—Nervous system disorder—Epirubicin—uterine cancer	4.91e-05	0.000447	CcSEcCtD
Aprepitant—Thrombocytopenia—Epirubicin—uterine cancer	4.91e-05	0.000447	CcSEcCtD
Aprepitant—Hypertension—Doxorubicin—uterine cancer	4.91e-05	0.000447	CcSEcCtD
Aprepitant—Tachycardia—Epirubicin—uterine cancer	4.89e-05	0.000445	CcSEcCtD
Aprepitant—Skin disorder—Epirubicin—uterine cancer	4.87e-05	0.000443	CcSEcCtD
Aprepitant—Hyperhidrosis—Epirubicin—uterine cancer	4.84e-05	0.000441	CcSEcCtD
Aprepitant—Chest pain—Doxorubicin—uterine cancer	4.84e-05	0.00044	CcSEcCtD
Aprepitant—Arthralgia—Doxorubicin—uterine cancer	4.84e-05	0.00044	CcSEcCtD
Aprepitant—Myalgia—Doxorubicin—uterine cancer	4.84e-05	0.00044	CcSEcCtD
Aprepitant—Anxiety—Doxorubicin—uterine cancer	4.82e-05	0.000439	CcSEcCtD
Aprepitant—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	4.8e-05	0.000437	CcSEcCtD
Aprepitant—Discomfort—Doxorubicin—uterine cancer	4.78e-05	0.000435	CcSEcCtD
Aprepitant—Anorexia—Epirubicin—uterine cancer	4.78e-05	0.000435	CcSEcCtD
Aprepitant—Dry mouth—Doxorubicin—uterine cancer	4.73e-05	0.000431	CcSEcCtD
Aprepitant—Hypotension—Epirubicin—uterine cancer	4.68e-05	0.000426	CcSEcCtD
Aprepitant—Confusional state—Doxorubicin—uterine cancer	4.68e-05	0.000426	CcSEcCtD
Aprepitant—Anaphylactic shock—Doxorubicin—uterine cancer	4.64e-05	0.000422	CcSEcCtD
Aprepitant—Oedema—Doxorubicin—uterine cancer	4.64e-05	0.000422	CcSEcCtD
Aprepitant—Infection—Doxorubicin—uterine cancer	4.61e-05	0.000419	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Epirubicin—uterine cancer	4.57e-05	0.000416	CcSEcCtD
Aprepitant—Shock—Doxorubicin—uterine cancer	4.56e-05	0.000415	CcSEcCtD
Aprepitant—Nervous system disorder—Doxorubicin—uterine cancer	4.55e-05	0.000414	CcSEcCtD
Aprepitant—Thrombocytopenia—Doxorubicin—uterine cancer	4.54e-05	0.000413	CcSEcCtD
Aprepitant—Insomnia—Epirubicin—uterine cancer	4.53e-05	0.000413	CcSEcCtD
Aprepitant—Tachycardia—Doxorubicin—uterine cancer	4.53e-05	0.000412	CcSEcCtD
Aprepitant—Skin disorder—Doxorubicin—uterine cancer	4.5e-05	0.00041	CcSEcCtD
Aprepitant—Paraesthesia—Epirubicin—uterine cancer	4.5e-05	0.00041	CcSEcCtD
Aprepitant—Hyperhidrosis—Doxorubicin—uterine cancer	4.48e-05	0.000408	CcSEcCtD
Aprepitant—Dyspnoea—Epirubicin—uterine cancer	4.47e-05	0.000407	CcSEcCtD
Aprepitant—Somnolence—Epirubicin—uterine cancer	4.46e-05	0.000406	CcSEcCtD
Aprepitant—Anorexia—Doxorubicin—uterine cancer	4.42e-05	0.000402	CcSEcCtD
Aprepitant—Dyspepsia—Epirubicin—uterine cancer	4.41e-05	0.000402	CcSEcCtD
Aprepitant—Decreased appetite—Epirubicin—uterine cancer	4.36e-05	0.000397	CcSEcCtD
Aprepitant—Hypotension—Doxorubicin—uterine cancer	4.33e-05	0.000394	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Epirubicin—uterine cancer	4.33e-05	0.000394	CcSEcCtD
Aprepitant—Fatigue—Epirubicin—uterine cancer	4.32e-05	0.000393	CcSEcCtD
Aprepitant—Pain—Epirubicin—uterine cancer	4.29e-05	0.00039	CcSEcCtD
Aprepitant—Constipation—Epirubicin—uterine cancer	4.29e-05	0.00039	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Doxorubicin—uterine cancer	4.22e-05	0.000385	CcSEcCtD
Aprepitant—Insomnia—Doxorubicin—uterine cancer	4.19e-05	0.000382	CcSEcCtD
Aprepitant—Paraesthesia—Doxorubicin—uterine cancer	4.16e-05	0.000379	CcSEcCtD
Aprepitant—Dyspnoea—Doxorubicin—uterine cancer	4.13e-05	0.000376	CcSEcCtD
Aprepitant—Feeling abnormal—Epirubicin—uterine cancer	4.13e-05	0.000376	CcSEcCtD
Aprepitant—Somnolence—Doxorubicin—uterine cancer	4.12e-05	0.000375	CcSEcCtD
Aprepitant—Gastrointestinal pain—Epirubicin—uterine cancer	4.1e-05	0.000373	CcSEcCtD
Aprepitant—Dyspepsia—Doxorubicin—uterine cancer	4.08e-05	0.000372	CcSEcCtD
Aprepitant—Decreased appetite—Doxorubicin—uterine cancer	4.03e-05	0.000367	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Doxorubicin—uterine cancer	4e-05	0.000364	CcSEcCtD
Aprepitant—Fatigue—Doxorubicin—uterine cancer	4e-05	0.000364	CcSEcCtD
Aprepitant—Urticaria—Epirubicin—uterine cancer	3.98e-05	0.000362	CcSEcCtD
Aprepitant—Pain—Doxorubicin—uterine cancer	3.97e-05	0.000361	CcSEcCtD
Aprepitant—Constipation—Doxorubicin—uterine cancer	3.97e-05	0.000361	CcSEcCtD
Aprepitant—Abdominal pain—Epirubicin—uterine cancer	3.96e-05	0.000361	CcSEcCtD
Aprepitant—Body temperature increased—Epirubicin—uterine cancer	3.96e-05	0.000361	CcSEcCtD
Aprepitant—Feeling abnormal—Doxorubicin—uterine cancer	3.82e-05	0.000348	CcSEcCtD
Aprepitant—Gastrointestinal pain—Doxorubicin—uterine cancer	3.79e-05	0.000345	CcSEcCtD
Aprepitant—Hypersensitivity—Epirubicin—uterine cancer	3.69e-05	0.000336	CcSEcCtD
Aprepitant—Urticaria—Doxorubicin—uterine cancer	3.68e-05	0.000335	CcSEcCtD
Aprepitant—Abdominal pain—Doxorubicin—uterine cancer	3.67e-05	0.000334	CcSEcCtD
Aprepitant—Body temperature increased—Doxorubicin—uterine cancer	3.67e-05	0.000334	CcSEcCtD
Aprepitant—Asthenia—Epirubicin—uterine cancer	3.6e-05	0.000327	CcSEcCtD
Aprepitant—Pruritus—Epirubicin—uterine cancer	3.55e-05	0.000323	CcSEcCtD
Aprepitant—Diarrhoea—Epirubicin—uterine cancer	3.43e-05	0.000312	CcSEcCtD
Aprepitant—Hypersensitivity—Doxorubicin—uterine cancer	3.42e-05	0.000311	CcSEcCtD
Aprepitant—Asthenia—Doxorubicin—uterine cancer	3.33e-05	0.000303	CcSEcCtD
Aprepitant—Dizziness—Epirubicin—uterine cancer	3.31e-05	0.000302	CcSEcCtD
Aprepitant—Pruritus—Doxorubicin—uterine cancer	3.28e-05	0.000299	CcSEcCtD
Aprepitant—Vomiting—Epirubicin—uterine cancer	3.19e-05	0.00029	CcSEcCtD
Aprepitant—Diarrhoea—Doxorubicin—uterine cancer	3.17e-05	0.000289	CcSEcCtD
Aprepitant—Rash—Epirubicin—uterine cancer	3.16e-05	0.000288	CcSEcCtD
Aprepitant—Dermatitis—Epirubicin—uterine cancer	3.16e-05	0.000287	CcSEcCtD
Aprepitant—Headache—Epirubicin—uterine cancer	3.14e-05	0.000286	CcSEcCtD
Aprepitant—Dizziness—Doxorubicin—uterine cancer	3.07e-05	0.000279	CcSEcCtD
Aprepitant—Nausea—Epirubicin—uterine cancer	2.98e-05	0.000271	CcSEcCtD
Aprepitant—Vomiting—Doxorubicin—uterine cancer	2.95e-05	0.000268	CcSEcCtD
Aprepitant—Rash—Doxorubicin—uterine cancer	2.92e-05	0.000266	CcSEcCtD
Aprepitant—Dermatitis—Doxorubicin—uterine cancer	2.92e-05	0.000266	CcSEcCtD
Aprepitant—Headache—Doxorubicin—uterine cancer	2.9e-05	0.000264	CcSEcCtD
Aprepitant—Nausea—Doxorubicin—uterine cancer	2.75e-05	0.000251	CcSEcCtD
Aprepitant—CYP1A2—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	1.39e-05	0.00342	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—STK11—uterine cancer	1.38e-05	0.0034	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—CCL2—uterine cancer	1.37e-05	0.00339	CbGpPWpGaD
Aprepitant—CYP3A4—Metapathway biotransformation—AKR1B10—uterine cancer	1.37e-05	0.00338	CbGpPWpGaD
Aprepitant—CYP2C19—Metapathway biotransformation—GPX3—uterine cancer	1.36e-05	0.00336	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—RNF43—uterine cancer	1.36e-05	0.00336	CbGpPWpGaD
Aprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—uterine cancer	1.36e-05	0.00335	CbGpPWpGaD
Aprepitant—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	1.32e-05	0.00325	CbGpPWpGaD
Aprepitant—TACR1—GPCR ligand binding—CCL2—uterine cancer	1.31e-05	0.00322	CbGpPWpGaD
Aprepitant—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	1.3e-05	0.00321	CbGpPWpGaD
Aprepitant—TACR1—G alpha (q) signalling events—PIK3CA—uterine cancer	1.3e-05	0.0032	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—SOCS3—uterine cancer	1.29e-05	0.00319	CbGpPWpGaD
Aprepitant—CYP2C19—Biological oxidations—CYP11A1—uterine cancer	1.28e-05	0.00317	CbGpPWpGaD
Aprepitant—CYP3A4—Metapathway biotransformation—AKR1B1—uterine cancer	1.27e-05	0.00314	CbGpPWpGaD
Aprepitant—CYP2C19—Metapathway biotransformation—CYP11A1—uterine cancer	1.27e-05	0.00312	CbGpPWpGaD
Aprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—uterine cancer	1.26e-05	0.00312	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—INHBA—uterine cancer	1.25e-05	0.00308	CbGpPWpGaD
Aprepitant—CYP2C9—Metapathway biotransformation—GPX3—uterine cancer	1.24e-05	0.00307	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—CDKN2B—uterine cancer	1.24e-05	0.00305	CbGpPWpGaD
Aprepitant—CYP3A5—Biological oxidations—CYP19A1—uterine cancer	1.22e-05	0.00301	CbGpPWpGaD
Aprepitant—CYP1A2—Metapathway biotransformation—AKR1C1—uterine cancer	1.21e-05	0.00299	CbGpPWpGaD
Aprepitant—CYP3A5—Metapathway biotransformation—CYP19A1—uterine cancer	1.21e-05	0.00297	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—IGF1R—uterine cancer	1.2e-05	0.00296	CbGpPWpGaD
Aprepitant—CYP2C19—Metapathway biotransformation—AKR1C3—uterine cancer	1.2e-05	0.00295	CbGpPWpGaD
Aprepitant—TACR3—GPCR downstream signaling—CXCL8—uterine cancer	1.2e-05	0.00295	CbGpPWpGaD
Aprepitant—CYP2C9—Biological oxidations—CYP11A1—uterine cancer	1.17e-05	0.00289	CbGpPWpGaD
Aprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—uterine cancer	1.16e-05	0.00287	CbGpPWpGaD
Aprepitant—CYP2C9—Metapathway biotransformation—CYP11A1—uterine cancer	1.16e-05	0.00285	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	1.14e-05	0.00281	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—SMAD3—uterine cancer	1.13e-05	0.00278	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—AKR1C1—uterine cancer	1.12e-05	0.00277	CbGpPWpGaD
Aprepitant—CYP2C9—Metapathway biotransformation—AKR1C3—uterine cancer	1.09e-05	0.00269	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—CXCL8—uterine cancer	1.09e-05	0.00268	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—FGFR2—uterine cancer	1.08e-05	0.00266	CbGpPWpGaD
Aprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—uterine cancer	1.08e-05	0.00265	CbGpPWpGaD
Aprepitant—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	1.07e-05	0.00264	CbGpPWpGaD
Aprepitant—CYP1A2—Metapathway biotransformation—GPX3—uterine cancer	1.06e-05	0.00262	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	1.04e-05	0.00256	CbGpPWpGaD
Aprepitant—TACR1—GPCR ligand binding—CXCL8—uterine cancer	1.03e-05	0.00255	CbGpPWpGaD
Aprepitant—CYP1A2—Biological oxidations—CYP11A1—uterine cancer	1e-05	0.00247	CbGpPWpGaD
Aprepitant—CYP1A2—Metapathway biotransformation—CYP11A1—uterine cancer	9.87e-06	0.00243	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—uterine cancer	9.6e-06	0.00237	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—uterine cancer	9.6e-06	0.00237	CbGpPWpGaD
Aprepitant—CYP2C19—Biological oxidations—CYP19A1—uterine cancer	9.45e-06	0.00233	CbGpPWpGaD
Aprepitant—CYP3A4—Metapathway biotransformation—AKR1C1—uterine cancer	9.35e-06	0.0023	CbGpPWpGaD
Aprepitant—CYP1A2—Metapathway biotransformation—AKR1C3—uterine cancer	9.32e-06	0.0023	CbGpPWpGaD
Aprepitant—CYP2C19—Metapathway biotransformation—CYP19A1—uterine cancer	9.32e-06	0.0023	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—ESR1—uterine cancer	9.21e-06	0.00227	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—SRD5A2—uterine cancer	9.09e-06	0.00224	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—NDUFB11—uterine cancer	9.09e-06	0.00224	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	8.88e-06	0.00219	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—NRAS—uterine cancer	8.71e-06	0.00215	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—AKR1C3—uterine cancer	8.65e-06	0.00213	CbGpPWpGaD
Aprepitant—CYP2C9—Biological oxidations—CYP19A1—uterine cancer	8.62e-06	0.00213	CbGpPWpGaD
Aprepitant—CYP2C9—Metapathway biotransformation—CYP19A1—uterine cancer	8.5e-06	0.0021	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—EP300—uterine cancer	8.43e-06	0.00208	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—uterine cancer	8.43e-06	0.00208	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—PGR—uterine cancer	8.43e-06	0.00208	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	8.24e-06	0.00203	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—STAR—uterine cancer	8.24e-06	0.00203	CbGpPWpGaD
Aprepitant—CYP3A4—Metapathway biotransformation—GPX3—uterine cancer	8.2e-06	0.00202	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—CCL2—uterine cancer	8.11e-06	0.002	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—YWHAE—uterine cancer	8.04e-06	0.00198	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—uterine cancer	7.99e-06	0.00197	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—uterine cancer	7.89e-06	0.00195	CbGpPWpGaD
Aprepitant—CYP3A4—Biological oxidations—CYP11A1—uterine cancer	7.72e-06	0.00191	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—FBXW7—uterine cancer	7.71e-06	0.0019	CbGpPWpGaD
Aprepitant—CYP3A4—Metapathway biotransformation—CYP11A1—uterine cancer	7.62e-06	0.00188	CbGpPWpGaD
Aprepitant—TACR3—GPCR downstream signaling—PIK3CA—uterine cancer	7.58e-06	0.00187	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—STAR—uterine cancer	7.52e-06	0.00185	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	7.52e-06	0.00185	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—KRAS—uterine cancer	7.5e-06	0.00185	CbGpPWpGaD
Aprepitant—CYP1A2—Biological oxidations—CYP19A1—uterine cancer	7.36e-06	0.00182	CbGpPWpGaD
Aprepitant—CYP1A2—Metapathway biotransformation—CYP19A1—uterine cancer	7.26e-06	0.00179	CbGpPWpGaD
Aprepitant—CYP3A4—Metapathway biotransformation—AKR1C3—uterine cancer	7.19e-06	0.00177	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—PIK3CA—uterine cancer	6.89e-06	0.0017	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—uterine cancer	6.79e-06	0.00167	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—ERBB2—uterine cancer	6.76e-06	0.00167	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—STK11—uterine cancer	6.74e-06	0.00166	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—CCL2—uterine cancer	6.71e-06	0.00165	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—STAR—uterine cancer	6.57e-06	0.00162	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—AKR1B1—uterine cancer	6.57e-06	0.00162	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—SRD5A2—uterine cancer	6.57e-06	0.00162	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—NDUFB11—uterine cancer	6.57e-06	0.00162	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—STAR—uterine cancer	6.42e-06	0.00158	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	6.42e-06	0.00158	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—CXCL8—uterine cancer	6.41e-06	0.00158	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—HRAS—uterine cancer	6.37e-06	0.00157	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—SOCS3—uterine cancer	6.31e-06	0.00156	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—CDKN1B—uterine cancer	6.26e-06	0.00154	CbGpPWpGaD
Aprepitant—TACR3—GPCR downstream signaling—AKT1—uterine cancer	6.19e-06	0.00153	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	6.05e-06	0.00149	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CDKN2B—uterine cancer	6.04e-06	0.00149	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—CTNNB1—uterine cancer	5.92e-06	0.00146	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—IGF1R—uterine cancer	5.86e-06	0.00145	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—CXCL8—uterine cancer	5.84e-06	0.00144	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—uterine cancer	5.77e-06	0.00142	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—PTEN—uterine cancer	5.77e-06	0.00142	CbGpPWpGaD
Aprepitant—CYP3A4—Biological oxidations—CYP19A1—uterine cancer	5.68e-06	0.0014	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—AKT1—uterine cancer	5.63e-06	0.00139	CbGpPWpGaD
Aprepitant—CYP3A4—Metapathway biotransformation—CYP19A1—uterine cancer	5.6e-06	0.00138	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	5.52e-06	0.00136	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—SMAD3—uterine cancer	5.51e-06	0.00136	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—EP300—uterine cancer	5.5e-06	0.00136	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—CXCL8—uterine cancer	5.3e-06	0.00131	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—FGFR2—uterine cancer	5.26e-06	0.0013	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—VEGFA—uterine cancer	5.21e-06	0.00128	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—POLD1—uterine cancer	5.16e-06	0.00127	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—NRAS—uterine cancer	5.14e-06	0.00127	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—NDUFB11—uterine cancer	5.08e-06	0.00125	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—SRD5A2—uterine cancer	5.08e-06	0.00125	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	4.93e-06	0.00122	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—AKR1C1—uterine cancer	4.82e-06	0.00119	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—AKR1B1—uterine cancer	4.75e-06	0.00117	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—STAR—uterine cancer	4.75e-06	0.00117	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	4.71e-06	0.00116	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	4.66e-06	0.00115	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—NDUFB11—uterine cancer	4.63e-06	0.00114	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—SRD5A2—uterine cancer	4.63e-06	0.00114	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—ESR1—uterine cancer	4.5e-06	0.00111	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	4.5e-06	0.00111	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—KRAS—uterine cancer	4.43e-06	0.00109	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—RRM2—uterine cancer	4.3e-06	0.00106	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—NRAS—uterine cancer	4.25e-06	0.00105	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	4.25e-06	0.00105	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—DCN—uterine cancer	4.17e-06	0.00103	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—PIK3CA—uterine cancer	4.07e-06	0.001	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CCL2—uterine cancer	3.96e-06	0.000977	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—NDUFB11—uterine cancer	3.96e-06	0.000976	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—SRD5A2—uterine cancer	3.96e-06	0.000976	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—TP53—uterine cancer	3.94e-06	0.000971	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—CYP11A1—uterine cancer	3.93e-06	0.000969	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	3.84e-06	0.000948	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—HRAS—uterine cancer	3.76e-06	0.000928	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—POLD1—uterine cancer	3.73e-06	0.000919	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—AKR1C3—uterine cancer	3.71e-06	0.000915	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—PIK3CA—uterine cancer	3.7e-06	0.000913	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—AKR1B1—uterine cancer	3.67e-06	0.000905	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—STAR—uterine cancer	3.67e-06	0.000905	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—KRAS—uterine cancer	3.66e-06	0.000903	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	3.63e-06	0.000895	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	3.63e-06	0.000895	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—AKR1C1—uterine cancer	3.49e-06	0.00086	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—PIK3CA—uterine cancer	3.36e-06	0.000829	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—STAR—uterine cancer	3.35e-06	0.000826	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—AKR1B1—uterine cancer	3.35e-06	0.000826	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—AKT1—uterine cancer	3.32e-06	0.00082	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	3.31e-06	0.000816	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—ERBB2—uterine cancer	3.3e-06	0.000814	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CXCL8—uterine cancer	3.13e-06	0.000772	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—HRAS—uterine cancer	3.11e-06	0.000767	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—RRM2—uterine cancer	3.11e-06	0.000766	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CDKN1B—uterine cancer	3.06e-06	0.000754	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—SRD5A2—uterine cancer	3.05e-06	0.000753	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—NDUFB11—uterine cancer	3.05e-06	0.000753	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—AKT1—uterine cancer	3.03e-06	0.000746	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—DCN—uterine cancer	3.02e-06	0.000744	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—STK11—uterine cancer	2.89e-06	0.000713	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—CYP19A1—uterine cancer	2.89e-06	0.000713	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CTNNB1—uterine cancer	2.89e-06	0.000713	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—POLD1—uterine cancer	2.88e-06	0.000711	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—AKR1B1—uterine cancer	2.86e-06	0.000706	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—STAR—uterine cancer	2.86e-06	0.000706	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—CYP11A1—uterine cancer	2.84e-06	0.000701	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	2.83e-06	0.000697	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—PTEN—uterine cancer	2.82e-06	0.000694	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—AKT1—uterine cancer	2.75e-06	0.000678	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—AKR1C1—uterine cancer	2.69e-06	0.000665	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—EP300—uterine cancer	2.69e-06	0.000662	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—AKR1C3—uterine cancer	2.68e-06	0.000662	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—POLD1—uterine cancer	2.63e-06	0.000648	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—VEGFA—uterine cancer	2.54e-06	0.000627	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—NRAS—uterine cancer	2.51e-06	0.00062	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—AKR1C1—uterine cancer	2.46e-06	0.000606	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—RRM2—uterine cancer	2.4e-06	0.000592	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—DCN—uterine cancer	2.33e-06	0.000575	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—POLD1—uterine cancer	2.24e-06	0.000554	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—AKR1B1—uterine cancer	2.21e-06	0.000544	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—STAR—uterine cancer	2.21e-06	0.000544	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—CYP11A1—uterine cancer	2.2e-06	0.000542	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—RRM2—uterine cancer	2.19e-06	0.00054	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—MTHFR—uterine cancer	2.17e-06	0.000536	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—KRAS—uterine cancer	2.16e-06	0.000533	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—DCN—uterine cancer	2.13e-06	0.000524	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—AKR1C1—uterine cancer	2.1e-06	0.000518	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—STK11—uterine cancer	2.09e-06	0.000516	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—CYP19A1—uterine cancer	2.09e-06	0.000516	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—AKR1C3—uterine cancer	2.07e-06	0.000512	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—CYP11A1—uterine cancer	2e-06	0.000494	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—PIK3CA—uterine cancer	1.99e-06	0.00049	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—TP53—uterine cancer	1.92e-06	0.000474	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—AKR1C3—uterine cancer	1.89e-06	0.000467	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—RRM2—uterine cancer	1.87e-06	0.000462	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—HRAS—uterine cancer	1.84e-06	0.000453	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—DCN—uterine cancer	1.82e-06	0.000448	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—POLD1—uterine cancer	1.73e-06	0.000427	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—CYP11A1—uterine cancer	1.71e-06	0.000422	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—AKT1—uterine cancer	1.62e-06	0.0004	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—AKR1C1—uterine cancer	1.62e-06	0.0004	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—AKR1C3—uterine cancer	1.62e-06	0.000399	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—STK11—uterine cancer	1.62e-06	0.000399	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—CYP19A1—uterine cancer	1.62e-06	0.000399	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—MTHFR—uterine cancer	1.57e-06	0.000387	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.52e-06	0.000374	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—CYP19A1—uterine cancer	1.47e-06	0.000363	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—STK11—uterine cancer	1.47e-06	0.000363	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.45e-06	0.000357	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—RRM2—uterine cancer	1.44e-06	0.000356	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—DCN—uterine cancer	1.4e-06	0.000346	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.38e-06	0.000341	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—CYP11A1—uterine cancer	1.32e-06	0.000326	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.32e-06	0.000325	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—STK11—uterine cancer	1.26e-06	0.000311	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—CYP19A1—uterine cancer	1.26e-06	0.000311	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—AKR1C3—uterine cancer	1.25e-06	0.000308	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—MTHFR—uterine cancer	1.21e-06	0.0003	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—PTEN—uterine cancer	1.21e-06	0.000298	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.18e-06	0.000292	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—EP300—uterine cancer	1.15e-06	0.000284	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.13e-06	0.000278	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—MTHFR—uterine cancer	1.11e-06	0.000273	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.07e-06	0.000264	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	9.76e-07	0.000241	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—STK11—uterine cancer	9.72e-07	0.00024	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—CYP19A1—uterine cancer	9.72e-07	0.00024	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—MTHFR—uterine cancer	9.46e-07	0.000233	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PTEN—uterine cancer	8.74e-07	0.000216	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—PIK3CA—uterine cancer	8.53e-07	0.00021	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	8.34e-07	0.000206	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—EP300—uterine cancer	8.33e-07	0.000206	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—MTHFR—uterine cancer	7.3e-07	0.00018	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—AKT1—uterine cancer	6.97e-07	0.000172	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PTEN—uterine cancer	6.76e-07	0.000167	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—EP300—uterine cancer	6.44e-07	0.000159	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PIK3CA—uterine cancer	6.17e-07	0.000152	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PTEN—uterine cancer	6.16e-07	0.000152	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—EP300—uterine cancer	5.88e-07	0.000145	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PTEN—uterine cancer	5.26e-07	0.00013	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—AKT1—uterine cancer	5.04e-07	0.000124	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—EP300—uterine cancer	5.02e-07	0.000124	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PIK3CA—uterine cancer	4.77e-07	0.000118	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PIK3CA—uterine cancer	4.35e-07	0.000107	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PTEN—uterine cancer	4.06e-07	0.0001	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—AKT1—uterine cancer	3.89e-07	9.6e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—EP300—uterine cancer	3.87e-07	9.56e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PIK3CA—uterine cancer	3.71e-07	9.16e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—AKT1—uterine cancer	3.55e-07	8.76e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—AKT1—uterine cancer	3.03e-07	7.48e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PIK3CA—uterine cancer	2.87e-07	7.07e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—AKT1—uterine cancer	2.34e-07	5.77e-05	CbGpPWpGaD
